Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Acimtamig by Affimed for Transformed Mycosis Fungoides: Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase...
Acimtamig by Affimed for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to...
Acimtamig by Affimed for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...
Acimtamig by Affimed for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...
Acimtamig by Affimed for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Risk adjusted net present value: What is the current valuation of Affimed's Acimtamig?
Acimtamig is a monoclonal antibody commercialized by Affimed, with a leading Phase II program in Anaplastic Large Cell Lymphoma (ALCL)....